DID-20 our answer to covid-19

Additional Information

The novel virus SARS-CoV-2 and the resulting disease COVID-19 have determined our lives for quite some time. A lot is still unclear and a lot had to be corrected from initial assumptions. But it is also clear: detection of the virus, a strong immune system and the correct disinfection are part of the key to the solution. DETECTION, IMMUNIZATION and DISINFECTION - DID-20

medical diagnostic service, medical test kits, dna test kits, drug test kits, vitamins, immune system

About Us

Company Principles

A holistic approach - support and strengthen the cell and the system
Nature as a role model and inspiration
An interdisciplinary, innovative and intercultural approach to research, development and manufacturing
A unique combination of tradition, experience and the latest scientific knowledge
An ecologically sustainable and resource-saving production

The Essentials in brief

sanPharma GmbH - founded in 1978 by Gerhard Schröder, taken over in 2014 by Dr. Thomas Wüstefeld, PhD
MEDsan GmbH incorporated by Dr. Thomas Wüstefeld, PhD
MEDsan Inc. incorporated by Dr. Thomas Wüstefeld, PhD & Dr. Jonathan Brenner, PhD
Continuous expansion of the product portfolio in our group of companies
Isopathic and immunobiological drugs
High bioavailable food supplements
Supportive medical cosmetics
State-of-the-art medical devices and technologies
Continually growing group of companies with over 280 employees
Worldwide sales in over 42 countries

Find out more

Comparison of 3 Commercial COVID-19 IgM/IgG Serology rTs

Why MEDsan?

Head-to-Head Accuracy Comparison of Three Commercial COVID-19 IgM/IgG Serology Rapid Tests

Background: Comparative data of SARS-CoV-2 IgM/IgG serology rapid diagnostic tests (RDTs) is scarce. We thus performed a head-to-head comparison of three RDTs.

Methods: In this unmatched case-control study, blood samples from 41 RT-PCR-confirmed COVID-19 cases and 50 negative controls were studied. The diagnostic accuracy of three commercially available COVID-19 RDTs: NTBIO (RDT-A), Orient-Gene (RDT-B), and MEDsan (RDT-C), against both a recombinant spike-expressing immunofluorescence assay (rIFA) and Euroimmun IgG ELISA, was assessed. RDT results concordant with the reference methods, and between whole blood and plasma, were established by the Kendall coefficient.

Results: COVID-19 cases’ median time from RT-PCR to serology was 22 days (interquartile range (IQR) 13–31 days). Whole-blood IgG detection with RDT-A, -B, and -C showed 0.93, 0.83, and 0.98 concordance with rIFA. Against rIFA, RDT-A sensitivity (SN) was 92% (95% CI: 78–98) and specificity (SP) 100% (95% CI: 91–100), RDT-B showed 87% SN (95% CI: 72–95) and 98% SP (95% CI: 88–100), and RDT-C 100% SN (95% CI: 88–100) and 98% SP (95% CI: 88–100). Against ELISA, SN and SP were above 90% for all three RDTs.

Conclusions: RDT-A and RDT-C displayed IgG detection SN and SP above 90% in whole blood. These RDTs could be considered in the absence of routine diagnostic serology facilities which were provided to the Geneva Reference Centre for Emerging Viral Diseases by the Swiss Red Cross and the Swiss National COVID-19 Science Task Force (https://ncs-tf.ch/en/).

MEDsan GmbH, Biological Health Solutions (Hamburg, Germany) hereafter, RDT-C.

When compared to rIFA, RDT-C (MEDsan) appeared to be the most satisfactory of the three RDT tested, with a concordance of 98%, a NPV of 100%, a PPV of 98%, a LR+ of 52, and an optimal LR-of 0.0.

Regarding the secondary endpoint (association with Euroimmun IgG ELISA) in whole blood, RDT-C (MEDsan) was also found to be close to optimal, with a concordance of 96%, a SN of 100%, a NPV of 100%, a SPof 96%, a PPV of 95%, and an optimal LR-of 0.0, butit also had the lowest LR+ (26.5) among the three RDTs.

To the best of our knowledge, only this study compared RDT performances against an immunoassay as the reference method.

For more information click here.

DID-20 our answer to COVID-19, medical test kits